{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:48:09Z","timestamp":1794473289512,"version":"4.9.1"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,7,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Advanced prostate cancer remains a major healthcare problem and cause of death in the United Kingdom. In contrast to many other cancer types, with the exception of poly (ADP-ribose) polymerase inhibition in DNA repair defective cancers, clinically actionable molecular subtypes are lacking. There are a number of studies that suggest the RAF-MEK-ERK-RSK cascade, a major oncogenic pathway, is activated in prostate cancer and this increases as the disease progresses. Mechanisms of activation are not dominated by pathogenic mutations in pathway proteins and include paracrine and autocrine mechanisms. There is strong evidence linking pathway activation with enhancing key proliferative signalling programmes and promoting cell survival in prostate cancer. Whilst inhibitors of the RAF-MEK-ERK-RSK pathway have demonstrated clinical utility in other cancers this has not been realised in prostate cancer. The reasons for this include a lack of predictive biomarkers for, and the unique landscape of pathway activation. Future studies need to identify robust predictive biomarkers, and improve the understanding of the fundamental biology of RAF-MEK-ERK-RSK activated prostate cancers if we are to successfully target this important sub-group.<\/jats:p>","DOI":"10.1038\/s41416-026-03441-x","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:58:21Z","timestamp":1778677101000},"page":"178-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Decoding the Raf-Mek-Erk-Rsk pathway in prostate cancer: from molecular mechanisms to clinical opportunities"],"prefix":"10.1038","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8507-3124","authenticated-orcid":false,"given":"Nick R.","family":"Waldron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Westaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Jim\u00e9nez-Vacas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3740-1612","authenticated-orcid":false,"given":"Adam","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"3441_CR1","doi-asserted-by":"publisher","unstructured":"Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Front Publ Health. 2022;10. https:\/\/doi.org\/10.3389\/fpubh.2022.811044.","DOI":"10.3389\/fpubh.2022.811044"},{"key":"3441_CR2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-pharmtox-052220-015912","volume":"62","author":"D Westaby","year":"2022","unstructured":"Westaby D, Fenor De La Maza MDLD, Paschalis A, Jimenez-Vacas JM, Welti J, De Bono J, et al. A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer. Annu Rev Pharmacol Toxicol. 2022;62:131\u201353.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"3441_CR3","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J De Bono","year":"2020","unstructured":"De Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382:2091\u2013102.","journal-title":"N Engl J Med"},{"key":"3441_CR4","doi-asserted-by":"publisher","first-page":"a011254","DOI":"10.1101\/cshperspect.a011254","volume":"4","author":"DK Morrison","year":"2012","unstructured":"Morrison DK. MAP Kinase Pathways. Cold Spring Harb Perspect Biol. 2012;4:a011254\u2013a.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"3441_CR5","doi-asserted-by":"publisher","unstructured":"Yuan J, Dong X, Yap J, Hu J. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J Hematology Oncol. 2020;13. https:\/\/doi.org\/10.1186\/s13045-020-00949-4.","DOI":"10.1186\/s13045-020-00949-4"},{"key":"3441_CR6","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.ijrobp.2003.06.002","volume":"58","author":"MD Marmor","year":"2004","unstructured":"Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB\/HER receptors. Int J Radiat Oncol *Biol *Phys. 2004;58:903\u201313.","journal-title":"Int J Radiat Oncol *Biol *Phys"},{"key":"3441_CR7","doi-asserted-by":"publisher","first-page":"19076","DOI":"10.1074\/jbc.M910329199","volume":"275","author":"J Yu","year":"2000","unstructured":"Yu J, Deuel TF, Kim H-RC. Platelet-derived Growth Factor (PDGF) Receptor-\u03b1 Activates c-Jun NH2-terminal Kinase-1 and Antagonizes PDGF Receptor-\u03b2-induced Phenotypic Transformation. J Biol Chem. 2000;275:19076\u201382.","journal-title":"J Biol Chem"},{"key":"3441_CR8","doi-asserted-by":"crossref","unstructured":"Bahar ME, Kim HJ, Kim DR. Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transd Targeted Therapy. 2023;8:455.","DOI":"10.1038\/s41392-023-01705-z"},{"key":"3441_CR9","doi-asserted-by":"crossref","unstructured":"Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK\/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020;19:1997\u20132007.","DOI":"10.3892\/etm.2020.8454"},{"key":"3441_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/cancers9050052","volume":"9","author":"P Wee","year":"2017","unstructured":"Wee P, Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers. 2017;9:52.","journal-title":"Cancers"},{"key":"3441_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","volume":"170","author":"DK Simanshu","year":"2017","unstructured":"Simanshu DK, Nissley DV, McCormick F. RAS Proteins and Their Regulators in Human Disease. Cell. 2017;170:17\u201333.","journal-title":"Cell"},{"key":"3441_CR12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41580-020-0255-7","volume":"21","author":"H Lavoie","year":"2020","unstructured":"Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 2020;21:607\u201332.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3441_CR13","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1007\/s00018-016-2297-8","volume":"73","author":"D Lake","year":"2016","unstructured":"Lake D, Corr\u00eaa SAL, M\u00fcller J. Negative feedback regulation of the ERK1\/2 MAPK pathway. Cell Mol Life Sci. 2016;73:4397\u2013413.","journal-title":"Cell Mol Life Sci"},{"key":"3441_CR14","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1128\/MCB.25.5.1830-1845.2005","volume":"25","author":"M Mandl","year":"2005","unstructured":"Mandl M, Slack DN, Keyse SM. Specific Inactivation and Nuclear Anchoring of Extracellular Signal-Regulated Kinase 2 by the Inducible Dual-Specificity Protein Phosphatase DUSP5. Mol Cell Biol. 2005;25:1830\u201345.","journal-title":"Mol Cell Biol"},{"key":"3441_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.trecan.2015.10.001","volume":"1","author":"MB Ryan","year":"2015","unstructured":"Ryan MB, Der CJ, Wang-Gillam A, Cox AD. Targeting RAS -mutant Cancers: Is ERK the Key? Trends Cancer. 2015;1:183\u201398.","journal-title":"Trends Cancer"},{"key":"3441_CR16","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior IA, Hood FE, Hartley JL. The Frequency of Ras Mutations in Cancer. Cancer Res. 2020;80:2969\u201374.","journal-title":"Cancer Res"},{"key":"3441_CR17","doi-asserted-by":"crossref","unstructured":"Yang X, Wu H. RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms. JHematol Oncol. 2024;17:108.","DOI":"10.1186\/s13045-024-01631-9"},{"key":"3441_CR18","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949\u201354.","journal-title":"Nature"},{"key":"3441_CR19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrc3760","volume":"14","author":"M Holderfield","year":"2014","unstructured":"Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014;14:455\u201367.","journal-title":"Nat Rev Cancer"},{"key":"3441_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.02.007","volume":"187","author":"AM Kidger","year":"2018","unstructured":"Kidger AM, Sipthorp J, Cook SJ. ERK1\/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1\/2-ERK1\/2 pathway. Pharmacol Therapeutics. 2018;187:45\u201360.","journal-title":"Pharmacol Therapeutics"},{"key":"3441_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrc3911","volume":"15","author":"N Ratner","year":"2015","unstructured":"Ratner N, Miller SJ. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer. 2015;15:290\u2013301.","journal-title":"Nat Rev Cancer"},{"key":"3441_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1056\/NEJM198601163140301","volume":"314","author":"MV Viola","year":"1986","unstructured":"Viola MV, Fromowitz F, Oravez S, Deb S, Finkel G, Lundy J, et al. Expression ofrasOncogene p21 in Prostate Cancer. N Engl J Med. 1986;314:133\u20137.","journal-title":"N Engl J Med"},{"key":"3441_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1155\/2008\/918087","volume":"24","author":"P Traynor","year":"2008","unstructured":"Traynor P, McGlynn LM, Mukhergee R, Grimsley SJS, Bartlett JMS, Edwards J. An increase in N-Ras expression is associated with development of hormone refractory prostate cancer in a subset of patients. Dis Markers. 2008;24:157\u201365.","journal-title":"Dis Markers"},{"key":"3441_CR24","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/bjc.1986.256","volume":"54","author":"A Robinson","year":"1986","unstructured":"Robinson A, Williams AR, Piris J, Spandidos DA, Wyllie AH. Evaluation of a monoclonal antibody to ras peptide, RAP-5, claimed to bind preferentially to cells of infiltrating carcinomas. Br J Cancer. 1986;54:877\u201383.","journal-title":"Br J Cancer"},{"key":"3441_CR25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/00005392-199501000-00083","volume":"153","author":"EC Bushman","year":"1995","unstructured":"Bushman EC, Nayak RN, Bushman W. Immunohistochemical Staining of ras p21: Staining in Benign and Malignant Prostate Tissue. J Urol. 1995;153:233\u20137.","journal-title":"J Urol"},{"key":"3441_CR26","doi-asserted-by":"publisher","first-page":"652","DOI":"10.6061\/clinics\/2013(05)12","volume":"68","author":"ST Reis","year":"2013","unstructured":"Reis ST, Timoszczuk LS, Pontes-Junior J, Viana N, Silva IA, Dip N, et al. The role of micro RNAs let7c, 100 and 218 expression and their target RAS, C-MYC, BUB1, RB, SMARCA5, LAMB3 and Ki-67 in prostate cancer. Clinics. 2013;68:652\u20137.","journal-title":"Clinics"},{"key":"3441_CR27","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/S0022-5347(05)68354-1","volume":"162","author":"DT Price","year":"1999","unstructured":"Price DT, Rocca GD, Guo C, Ballo MS, Schwinn DA, Luttrell LM. Activation of extracellular Signal-Regulated kinase in human prostate cancer. J Urol. 1999;162:1537\u201342.","journal-title":"J Urol"},{"key":"3441_CR28","first-page":"279","volume":"59","author":"D Gioeli","year":"1999","unstructured":"Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr., Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 1999;59:279\u201384.","journal-title":"Cancer Res"},{"key":"3441_CR29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41391-019-0134-5","volume":"22","author":"NG Nickols","year":"2019","unstructured":"Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, et al. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019;22:531\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3441_CR30","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1158\/0008-5472.CAN-18-2812","volume":"79","author":"S Li","year":"2019","unstructured":"Li S, Fong K-W, Gritsina G, Zhang A, Zhao JC, Kim J, et al. Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. Cancer Res. 2019;79:2580\u201392.","journal-title":"Cancer Res"},{"key":"3441_CR31","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1158\/0008-5472.CAN-04-3151","volume":"65","author":"DE Clark","year":"2005","unstructured":"Clark DE, Errington TM, Smith JA, Frierson HF, Weber MJ, Lannigan DA. The Serine\/Threonine Protein Kinase, p90 Ribosomal S6 Kinase, Is an Important Regulator of Prostate Cancer Cell Proliferation. Cancer Res. 2005;65:3108\u201316.","journal-title":"Cancer Res"},{"key":"3441_CR32","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1158\/1541-7786.MCR-14-0384-T","volume":"13","author":"G Yu","year":"2015","unstructured":"Yu G, Lee Y-C, Cheng C-J, Wu C-F, Song JH, Gallick GE, et al. RSK Promotes Prostate Cancer Progression in Bone through ING3, CKAP2, and PTK6-Mediated Cell Survival. Mol Cancer Res. 2015;13:348\u201357.","journal-title":"Mol Cancer Res"},{"key":"3441_CR33","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1200\/JCO.2023.41.6_suppl.257","volume":"41","author":"EM Ledet","year":"2023","unstructured":"Ledet EM, Mauer E, Chao CY, Sartor AO. Pathogenic BRAF mutations in prostate cancer: Frequency and distribution. J Clin Oncol. 2023;41:257.","journal-title":"J Clin Oncol"},{"key":"3441_CR34","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1158\/1078-0432.CCR-23-1393","volume":"29","author":"A Chehrazi-Raffle","year":"2023","unstructured":"Chehrazi-Raffle A, Tukachinsky H, Toye E, Sivakumar S, Schrock AB, Bergom HE, et al. Unique Spectrum of Activating BRAF Alterations in Prostate Cancer. Clin Cancer Res. 2023;29:3948\u201357.","journal-title":"Clin Cancer Res"},{"key":"3441_CR35","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"A Abeshouse","year":"2015","unstructured":"Abeshouse A, Ahn J, Akbani R, Ally A, Amin S, Christopher, et al. The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015;163:1011\u201325.","journal-title":"Cell"},{"key":"3441_CR36","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci. 2019;116:11428\u201336.","journal-title":"Proc Natl Acad Sci"},{"key":"3441_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative Genomic Profiling of Human Prostate Cancer. Cancer Cell. 2010;18:11\u201322.","journal-title":"Cancer Cell"},{"key":"3441_CR38","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.ccell.2024.08.018","volume":"42","author":"B Cali","year":"2024","unstructured":"Cali B, Troiani M, Bressan S, Attanasio G, Merler S, Moscarda V, et al. Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer. Cancer Cell. 2024;42:1676\u201392 e11.","journal-title":"Cancer Cell"},{"key":"3441_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112377","volume":"42","author":"I Steiner","year":"2023","unstructured":"Steiner I, Flores-Tellez TDNJ, Mevel R, Ali A, Wang P, Schofield P, et al. Autocrine activation of MAPK signaling mediates intrinsic tolerance to androgen deprivation in LY6D prostate cancer cells. Cell Rep. 2023;42:112377.","journal-title":"Cell Rep"},{"key":"3441_CR40","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","volume":"32","author":"EG Bluemn","year":"2017","unstructured":"Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, et al. Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. Cancer Cell. 2017;32:474.","journal-title":"Cancer Cell"},{"key":"3441_CR41","doi-asserted-by":"crossref","unstructured":"Wei G, Zhang X, Liu S, Hou W, Dai Z. Comprehensive data mining reveals RTK\/RAS signaling pathway as a promoter of prostate cancer lineage plasticity through transcription factors and CNV. Scientific Rep. 2024;14:11688.","DOI":"10.1038\/s41598-024-62256-z"},{"key":"3441_CR42","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1158\/1541-7786.MCR-20-0974","volume":"19","author":"W Liu","year":"2021","unstructured":"Liu W, Xie A, Tu C, Liu W. REX-1 Represses RASSF1a and Activates the MEK\/ERK Pathway to Promote Tumorigenesis in Prostate Cancer. Mol Cancer Res. 2021;19:1666\u201375.","journal-title":"Mol Cancer Res"},{"key":"3441_CR43","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1038\/bjc.2011.163","volume":"104","author":"R Mukherjee","year":"2011","unstructured":"Mukherjee R, McGuinness DH, McCall P, Underwood MA, Seywright M, Orange C, et al. Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer. Br J Cancer. 2011;104:1920\u20138.","journal-title":"Br J Cancer"},{"key":"3441_CR44","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/pros.20211","volume":"64","author":"R Mukherjee","year":"2005","unstructured":"Mukherjee R, Bartlett JMS, Krishna NS, Underwood MA, Edwards J. Raf-1 expression may influence progression to androgen insensitive prostate cancer. Prostate. 2005;64:101\u20137.","journal-title":"Prostate"},{"key":"3441_CR45","doi-asserted-by":"publisher","first-page":"TPS275","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS275","volume":"38","author":"Y Numan","year":"2020","unstructured":"Numan Y, Zhao J, Tang S, Zhang Y, Zhang Q, Jovanovic B, et al. Chemokine signaling and MAPK\/ERK pathway for advanced prostate cancer treatment response. J Clin Oncol. 2020;38:TPS275\u2013TPS.","journal-title":"J Clin Oncol"},{"key":"3441_CR46","first-page":"845","volume":"6","author":"S Meloche","year":"1992","unstructured":"Meloche S, Seuwen K, Pag\u00e8s G, Pouyss\u00e9gur J. Biphasic and synergistic activation of p44mapk (ERK1) by growth factors: correlation between late phase activation and mitogenicity. Mol Endocrinol. 1992;6:845\u201354.","journal-title":"Mol Endocrinol"},{"key":"3441_CR47","doi-asserted-by":"publisher","first-page":"23589","DOI":"10.1074\/jbc.270.40.23589","volume":"270","author":"C Albanese","year":"1995","unstructured":"Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A, et al. Transforming p21 Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions. J Biol Chem. 1995;270:23589\u201397.","journal-title":"J Biol Chem"},{"key":"3441_CR48","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/1521-1878(200009)22:9<818::AID-BIES7>3.0.CO;2-6","volume":"22","author":"K Roovers","year":"2000","unstructured":"Roovers K, Assoian RK. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. BioEssays. 2000;22:818\u201326.","journal-title":"BioEssays"},{"key":"3441_CR49","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1128\/MCB.00131-10","volume":"30","author":"L Voisin","year":"2010","unstructured":"Voisin L, Saba-El-Leil MK, Julien C, Fr\u00e9min C, Meloche S. Genetic Demonstration of a Redundant Role of Extracellular Signal-Regulated Kinase 1 (ERK1) and ERK2 Mitogen-Activated Protein Kinases in Promoting Fibroblast Proliferation. Mol Cell Biol. 2010;30:2918\u201332.","journal-title":"Mol Cell Biol"},{"key":"3441_CR50","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1111\/j.1349-7006.2007.00604.x","volume":"98","author":"T Yamaguchi","year":"2007","unstructured":"Yamaguchi T, Yoshida T, Kurachi R, Kakegawa J, Hori Y, Nanayama T, et al. Identification of JTP-70902, a p15INK4b-inductive compound, as a novel MEK1\/2 inhibitor. Cancer Sci. 2007;98:1809\u201316.","journal-title":"Cancer Sci"},{"key":"3441_CR51","doi-asserted-by":"publisher","first-page":"20608","DOI":"10.1074\/jbc.271.34.20608","volume":"271","author":"JN Lavoie","year":"1996","unstructured":"Lavoie JN, L\u2019Allemain G, Brunet A, M\u00fcller R, Pouyss\u00e9gur J. Cyclin D1 Expression Is Regulated Positively by the p42\/p44 and Negatively by the p38\/HOG Pathway. J Biol Chem. 1996;271:20608\u201316.","journal-title":"J Biol Chem"},{"key":"3441_CR52","first-page":"3635","volume":"9","author":"JI Daksis","year":"1994","unstructured":"Daksis JI, Lu RY, Facchini LM, Marhin WW, Penn LJZ. Myc Induces Cyclin D1 Expression in the Absence of De-Novo Protein-Synthesis and Links Mitogen-Stimulated Signal-Transduction to the Cell-Cycle. Oncogene. 1994;9:3635\u201345.","journal-title":"Oncogene"},{"key":"3441_CR53","doi-asserted-by":"publisher","first-page":"49254","DOI":"10.1074\/jbc.M306614200","volume":"278","author":"N Fujita","year":"2003","unstructured":"Fujita N, Sato S, Tsuruo T. Phosphorylation of p27Kip1 at Threonine 198 by p90 Ribosomal Protein S6 Kinases Promotes Its Binding to 14-3-3 and Cytoplasmic Localization. J Biol Chem. 2003;278:49254\u201360.","journal-title":"J Biol Chem"},{"key":"3441_CR54","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1128\/MCB.01758-08","volume":"29","author":"CY Hwang","year":"2009","unstructured":"Hwang CY, Lee C, Kwon K-S. Extracellular Signal-Regulated Kinase 2-Dependent Phosphorylation Induces Cytoplasmic Localization and Degradation of p21Cip1. Mol Cell Biol. 2009;29:3379\u201389.","journal-title":"Mol Cell Biol"},{"key":"3441_CR55","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1101\/gad.12.19.3008","volume":"12","author":"AW Lin","year":"1998","unstructured":"Lin AW, Barradas M, Stone JC, Van Aelst L, Serrano M, Lowe SW. Premature senescence involving p53 and p16 is activated in response to constitutive MEK\/MAPK mitogenic signaling. Genes Dev. 1998;12:3008\u201319.","journal-title":"Genes Dev"},{"key":"3441_CR56","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ng1054","volume":"33","author":"PM Pollock","year":"2003","unstructured":"Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19\u201320.","journal-title":"Nat Genet"},{"key":"3441_CR57","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1038\/onc.2011.160","volume":"30","author":"G Maurer","year":"2011","unstructured":"Maurer G, Tarkowski B, Baccarini M. Raf kinases in cancer\u2013roles and therapeutic opportunities. Oncogene. 2011;30:3477\u201388.","journal-title":"Oncogene"},{"key":"3441_CR58","doi-asserted-by":"crossref","unstructured":"Yap J, Yuan J, Ng WH, Chen GB, Sim YRM, Goh KC, et al. BRAF(V600E) mutation together with loss of Trp53 or pTEN drives the origination of hairy cell leukemia from B-lymphocytes. Molecular Cancer. 2023;22:125.","DOI":"10.1186\/s12943-023-01817-8"},{"key":"3441_CR59","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1158\/0008-5472.CAN-11-3132","volume":"72","author":"DJ Mulholland","year":"2012","unstructured":"Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, et al. Pten Loss and RAS\/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem\/Progenitor Cells. Cancer Res. 2012;72:1878\u201389.","journal-title":"Cancer Res"},{"key":"3441_CR60","first-page":"113","volume":"14","author":"G Wilding","year":"1992","unstructured":"Wilding G. The importance of steroid hormones in prostate cancer. Cancer Surv. 1992;14:113\u201330.","journal-title":"Cancer Surv"},{"key":"3441_CR61","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1073\/pnas.96.10.5458","volume":"96","author":"S Yeh","year":"1999","unstructured":"Yeh S, Lin H-K, Kang H-Y, Thin TH, Lin M-F, Chang C. From HER2\/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci. 1999;96:5458\u201363.","journal-title":"Proc Natl Acad Sci"},{"key":"3441_CR62","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/cas.14695","volume":"112","author":"M Shiota","year":"2021","unstructured":"Shiota M, Sekino Y, Tsukahara S, Abe T, Kinoshita F, Imada K, et al. Gene amplification of YB-1 in castration-resistant prostate cancer in association with aberrant androgen receptor expression. Cancer Sci. 2021;112:323\u201330.","journal-title":"Cancer Sci"},{"key":"3441_CR63","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1530\/ERC-11-0017","volume":"18","author":"M Shiota","year":"2011","unstructured":"Shiota M, Takeuchi A, Song Y, Yokomizo A, Kashiwagi E, Uchiumi T, et al. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression. Endocr Relat Cancer. 2011;18:505\u201317.","journal-title":"Endocr Relat Cancer"},{"key":"3441_CR64","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/pros.22813","volume":"74","author":"M Shiota","year":"2014","unstructured":"Shiota M, Yokomizo A, Takeuchi A, Itsumi M, Imada K, Kashiwagi E, et al. Inhibition of RSK\/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer. Prostate. 2014;74:959\u201369.","journal-title":"Prostate"},{"key":"3441_CR65","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s00432-018-2696-3","volume":"144","author":"C Ciccarelli","year":"2018","unstructured":"Ciccarelli C, Di Rocco A, Gravina GL, Mauro A, Festuccia C, Del Fattore A, et al. Disruption of MEK\/ERK\/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo. J Cancer Res Clin Oncol. 2018;144:1685\u201399.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3441_CR66","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ccell.2023.05.016","volume":"41","author":"H Wang","year":"2023","unstructured":"Wang H, Li N, Liu Q, Guo J, Pan Q, Cheng B, et al. Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. Cancer Cell. 2023;41:1345\u201362.e9.","journal-title":"Cancer Cell"},{"key":"3441_CR67","doi-asserted-by":"publisher","first-page":"20605","DOI":"10.1073\/pnas.1306328110","volume":"110","author":"C Chen","year":"2013","unstructured":"Chen C, Zhang L, Huang N-J, Huang B, Kornbluth S. Suppression of DNA-damage checkpoint signaling by Rsk-mediated phosphorylation of Mre11. Proc Natl Acad Sci. 2013;110:20605\u201310.","journal-title":"Proc Natl Acad Sci"},{"key":"3441_CR68","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1111\/cas.15280","volume":"113","author":"M Ushijima","year":"2022","unstructured":"Ushijima M, Shiota M, Matsumoto T, Kashiwagi E, Inokuchi J, Eto M. An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer. Cancer Sci. 2022;113:1731\u20138.","journal-title":"Cancer Sci"},{"key":"3441_CR69","doi-asserted-by":"crossref","unstructured":"Kim M, Liu J, Zhang Y, Wang R, Goettl R, Grasso J, et al. RSK1-driven TRIM28\/E2F1 feedback loop promotes castration-resistant prostate cancer progression. J Clin Investig. 2025;135:e185119.","DOI":"10.1172\/JCI185119"},{"key":"3441_CR70","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/cdd.2017.186","volume":"25","author":"J Kale","year":"2018","unstructured":"Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2018;25:65\u201380.","journal-title":"Cell Death Differ"},{"key":"3441_CR71","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1038\/sj.emboj.7601723","volume":"26","author":"KE Ewings","year":"2007","unstructured":"Ewings KE, Hadfield-Moorhouse K, Wiggins CM, Wickenden JA, Balmanno K, Gilley R, et al. ERK1\/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J. 2007;26:2856\u201367.","journal-title":"EMBO J"},{"key":"3441_CR72","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1038\/sj.onc.1206792","volume":"22","author":"F Luciano","year":"2003","unstructured":"Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G, et al. Phosphorylation of Bim-EL by Erk1\/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene. 2003;22:6785\u201393.","journal-title":"Oncogene"},{"key":"3441_CR73","doi-asserted-by":"publisher","first-page":"e13026","DOI":"10.1371\/journal.pone.0013026","volume":"5","author":"J Meng","year":"2010","unstructured":"Meng J, Fang B, Liao Y, Chresta CM, Smith PD, Roth JA. Apoptosis Induction by MEK Inhibition in Human Lung Cancer Cells Is Mediated by Bim. PLoS ONE. 2010;5:e13026.","journal-title":"PLoS ONE"},{"key":"3441_CR74","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1172\/JCI35437","volume":"118","author":"MS Cragg","year":"2008","unstructured":"Cragg MS, Jansen ES, Cook M, Harris C, Strasser A, Scott CL. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Investig. 2008;118:3651\u20139.","journal-title":"J Clin Investig"},{"key":"3441_CR75","doi-asserted-by":"publisher","first-page":"5301","DOI":"10.1038\/sj.onc.1207692","volume":"23","author":"AM Domina","year":"2004","unstructured":"Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene. 2004;23:5301\u201315.","journal-title":"Oncogene"},{"key":"3441_CR76","doi-asserted-by":"publisher","first-page":"29533","DOI":"10.1074\/jbc.M506514200","volume":"280","author":"Y-L Yu","year":"2005","unstructured":"Yu Y-L, Chiang Y-J, Chen Y-C, Papetti M, Juo C-G, Skoultchi AI, et al. MAPK-mediated Phosphorylation of GATA-1 Promotes Bcl-X Expression and Cell Survival. J Biol Chem. 2005;280:29533\u201342.","journal-title":"J Biol Chem"},{"key":"3441_CR77","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0","volume":"79","author":"MJ Boucher","year":"2000","unstructured":"Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N. MEK\/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem. 2000;79:355\u201369.","journal-title":"J Cell Biochem"},{"key":"3441_CR78","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1158\/1535-7163.MCT-19-0858","volume":"19","author":"B-R Wei","year":"2020","unstructured":"Wei B-R, Hoover SB, Peer CJ, Dwyer JE, Adissu HA, Shankarappa P, et al. Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1\/2 Inhibition in a Preclinical Model of Mucosal Melanoma. Mol Cancer Therapeutics. 2020;19:2308\u201318.","journal-title":"Mol Cancer Therapeutics"},{"key":"3441_CR79","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/jcb.20533","volume":"96","author":"K Tantivejkul","year":"2005","unstructured":"Tantivejkul K, Loberg RD, Mawocha SC, Day LL, John LS, Pienta BA, et al. PAR1-mediated NF\u03baB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J Cell Biochem. 2005;96:641\u201352.","journal-title":"J Cell Biochem"},{"key":"3441_CR80","doi-asserted-by":"crossref","unstructured":"Montero J, Gstalder C, Kim DJ, Sadowicz D, Miles W, Manos M, et al. Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. Nat Commun. 2019;10:5157.","DOI":"10.1038\/s41467-019-12477-y"},{"key":"3441_CR81","doi-asserted-by":"publisher","first-page":"37246","DOI":"10.1074\/jbc.M007732200","volume":"275","author":"C Bertolotto","year":"2000","unstructured":"Bertolotto C, Maulon L, Filippa N, Baier G, Auberger P. Protein Kinase C \u03b8 and \u03b5 Promote T-cell Survival by a Rsk-dependent Phosphorylation and Inactivation of BAD. J Biol Chem. 2000;275:37246\u201350.","journal-title":"J Biol Chem"},{"key":"3441_CR82","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/ijc.11413","volume":"107","author":"S Zelivianski","year":"2003","unstructured":"Zelivianski S, Spellman M, Kellerman M, Kakitelashvilli V, Zhou XW, Lugo E, et al. ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer. 2003;107:478\u201385.","journal-title":"Int J Cancer"},{"key":"3441_CR83","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/2159-8274.CD-10-0022","volume":"1","author":"X-S Wang","year":"2011","unstructured":"Wang X-S, Shankar S, Dhanasekaran SM, Ateeq B, Sasaki AT, Jing X, et al. Characterization of KRAS Rearrangements in Metastatic Prostate Cancer. Cancer Discov. 2011;1:35\u201343.","journal-title":"Cancer Discov"},{"key":"3441_CR84","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3892\/ijmm.2014.1679","volume":"33","author":"JS Park","year":"2014","unstructured":"Park JS, Kwon JK, Kim HR, Kim HJ, Kim BS, Jung JY. Farnesol induces apoptosis of DU145 prostate cancer cells through the PI3K\/Akt and MAPK pathways. Int J Mol Med. 2014;33:1169\u201376.","journal-title":"Int J Mol Med"},{"key":"3441_CR85","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/1541-7786.MCR-13-0029-T","volume":"11","author":"K Hatano","year":"2013","unstructured":"Hatano K, Yamaguchi S, Nimura K, Murakami K, Nagahara A, Fujita K, et al. Residual Prostate Cancer Cells after Docetaxel Therapy Increase the Tumorigenic Potential via Constitutive Signaling of CXCR4, ERK1\/2 and c-Myc. Mol Cancer Res. 2013;11:1088\u2013100.","journal-title":"Mol Cancer Res"},{"key":"3441_CR86","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.tcb.2013.07.006","volume":"23","author":"K Fernald","year":"2013","unstructured":"Fernald K, Kurokawa M. Evading apoptosis in cancer. Trends Cell Biol. 2013;23:620\u201333.","journal-title":"Trends Cell Biol"},{"key":"3441_CR87","doi-asserted-by":"publisher","first-page":"6635","DOI":"10.1038\/sj.onc.1203076","volume":"18","author":"X Fang","year":"1999","unstructured":"Fang X, Yu S, Eder A, Mao M, Bast RC, Boyd D, et al. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene. 1999;18:6635\u201340.","journal-title":"Oncogene"},{"key":"3441_CR88","first-page":"756","volume":"22","author":"M Beltran","year":"2008","unstructured":"Beltran M, Puig I, Pe\u00f1a C, Garc\u00eda JM, \u00c1lvarez AB, Pe\u00f1a R, et al. A natural antisense transcript regulates Zeb2\/Sip1 gene expression during Snail1-induced epithelial\u2013mesenchymal transition. Genes &amp. Development. 2008;22:756\u201369.","journal-title":"Development"},{"key":"3441_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-61","volume":"13","author":"N Selvaraj","year":"2014","unstructured":"Selvaraj N, Budka JA, Ferris MW, Jerde TJ, Hollenhorst PC. Prostate cancer ETS rearrangements switch a cell migration gene expression program from RAS\/ERK to PI3K\/AKT regulation. Mol Cancer. 2014;13:61.","journal-title":"Mol Cancer"},{"key":"3441_CR90","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10911-010-9178-9","volume":"15","author":"DS Micalizzi","year":"2010","unstructured":"Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-Mesenchymal Transition in Cancer: Parallels Between Normal Development and Tumor Progression. J Mammary Gland Biol Neoplasia. 2010;15:117\u201334.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"3441_CR91","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1093\/carcin\/bgs227","volume":"33","author":"MD Amatangelo","year":"2012","unstructured":"Amatangelo MD, Goodyear S, Varma D, Stearns ME. c-Myc expression and MEK1-induced Erk2 nuclear localization are required for TGF-beta induced epithelial\u2013mesenchymal transition and invasion in prostate cancer. Carcinogenesis. 2012;33:1965\u201375.","journal-title":"Carcinogenesis"},{"key":"3441_CR92","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3390\/cancers13051158","volume":"13","author":"D Mart\u00ednez-Mart\u00ednez","year":"2021","unstructured":"Mart\u00ednez-Mart\u00ednez D, Toledo Lobo M-V, Baquero P, Ropero S, Angulo JC, Chiloeches A, et al. Downregulation of Snail by DUSP1 Impairs Cell Migration and Invasion through the Inactivation of JNK and ERK and Is Useful as a Predictive Factor in the Prognosis of Prostate Cancer. Cancers. 2021;13:1158.","journal-title":"Cancers"},{"key":"3441_CR93","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1038\/s41388-018-0582-8","volume":"38","author":"S Papa","year":"2019","unstructured":"Papa S, Choy PM, Bubici C. The ERK and JNK pathways in the regulation of metabolic reprogramming. Oncogene. 2019;38:2223\u201340.","journal-title":"Oncogene"},{"key":"3441_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.101675","volume":"298","author":"M Jeon","year":"2022","unstructured":"Jeon M, Chauhan KM, Szeto GL, Kyoung M, An S. Subcellular regulation of glucose metabolism through multienzyme glucosome assemblies by EGF\u2013ERK1\/2 signaling pathways. J Biol Chem. 2022;298:101675.","journal-title":"J Biol Chem"},{"key":"3441_CR95","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41586-018-0350-5","volume":"559","author":"D Wu","year":"2018","unstructured":"Wu D, Hu D, Chen H, Shi G, Fetahu IS, Wu F, et al. Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer. Nature. 2018;559:637\u201341.","journal-title":"Nature"},{"key":"3441_CR96","doi-asserted-by":"publisher","first-page":"21797","DOI":"10.1074\/jbc.C000023200","volume":"275","author":"RC Osthus","year":"2000","unstructured":"Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, et al. Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc. J Biol Chem. 2000;275:21797\u2013800.","journal-title":"J Biol Chem"},{"key":"3441_CR97","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1158\/0008-5472.CAN-21-0914","volume":"82","author":"L Ippolito","year":"2022","unstructured":"Ippolito L, Comito G, Parri M, Iozzo M, Duatti A, Virgilio F, et al. Lactate Rewires Lipid Metabolism and Sustains a Metabolic\u2013Epigenetic Axis in Prostate Cancer. Cancer Res. 2022;82:1267\u201382.","journal-title":"Cancer Res"},{"key":"3441_CR98","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/cac2.12374","volume":"42","author":"T Ge","year":"2022","unstructured":"Ge T, Gu X, Jia R, Ge S, Chai P, Zhuang A, et al. Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities. Cancer Commun. 2022;42:1049\u201382.","journal-title":"Cancer Commun"},{"key":"3441_CR99","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1158\/1078-0432.CCR-22-3350","volume":"29","author":"K Chaudagar","year":"2023","unstructured":"Chaudagar K, Hieromnimon HM, Khurana R, Labadie B, Hirz T, Mei S, et al. Reversal of Lactate and PD-1\u2013mediated Macrophage Immunosuppression Controls Growth of PTEN\/p53-deficient Prostate Cancer. Clin Cancer Res. 2023;29:1952\u201368.","journal-title":"Clin Cancer Res"},{"key":"3441_CR100","doi-asserted-by":"crossref","unstructured":"Ruiz De Porras V, Bernat-Peguera A, Alcon C, Laguia F, Fern\u00e1ndez-Saorin M, Jim\u00e9nez N, et al. Dual inhibition of MEK and PI3K\u03b2\/\u03b4\u2013a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer. FrontPharmacol. 2024;15:1331648.","DOI":"10.3389\/fphar.2024.1331648"},{"key":"3441_CR101","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.semcancer.2022.02.017","volume":"86","author":"M Mughees","year":"2022","unstructured":"Mughees M, Kaushal JB, Sharma G, Wajid S, Batra SK, Siddiqui JA. Chemokines and cytokines: Axis and allies in prostate cancer pathogenesis. Semin Cancer Biol. 2022;86:497\u2013512.","journal-title":"Semin Cancer Biol"},{"key":"3441_CR102","doi-asserted-by":"crossref","unstructured":"Avery TY, K\u00f6hler N, Zeiser R, Brummer T, Ruess DA. Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation. Front Oncol. 2022;12.","DOI":"10.3389\/fonc.2022.931774"},{"key":"3441_CR103","doi-asserted-by":"crossref","unstructured":"Yang L, Guo P, Wang P, Wang W, Liu J. IL-6\/ERK signaling pathway participates in type I IFN-programmed, unconventional M2-like macrophage polarization. Scientific Rep. 2023;13:1827.","DOI":"10.1038\/s41598-022-23721-9"},{"key":"3441_CR104","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.21.01601","volume":"40","author":"R Dummer","year":"2022","unstructured":"Dummer R, Long GV, Robert C, Tawbi HA, Flaherty KT, Ascierto PA, et al. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600\u2013Mutant Unresectable or Metastatic Melanoma. J Clin Oncol. 2022;40:1428\u201338.","journal-title":"J Clin Oncol"},{"key":"3441_CR105","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.4049\/jimmunol.0900848","volume":"183","author":"KA Shafer-Weaver","year":"2009","unstructured":"Shafer-Weaver KA, Anderson MJ, Stagliano K, Malyguine A, Greenberg NM, Hurwitz AA. Cutting Edge: Tumor-Specific CD8+ T Cells Infiltrating Prostatic Tumors Are Induced to Become Suppressor Cells. J Immunol. 2009;183:4848\u201352.","journal-title":"J Immunol"},{"key":"3441_CR106","doi-asserted-by":"publisher","first-page":"e1197","DOI":"10.1634\/theoncologist.2018-0876","volume":"24","author":"JJ Luke","year":"2019","unstructured":"Luke JJ. Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma. Oncologist. 2019;24:e1197\u2013e211.","journal-title":"Oncologist"},{"key":"3441_CR107","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","volume":"37","author":"M Dankner","year":"2018","unstructured":"Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018;37:3183\u201399.","journal-title":"Oncogene"},{"key":"3441_CR108","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ccell.2015.08.001","volume":"28","author":"Z Yao","year":"2015","unstructured":"Yao Z, Neilawattie, Tao A, Gao Y, Luo L, Li Q, et al. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer Cell. 2015;28:370\u201383.","journal-title":"Cancer Cell"},{"key":"3441_CR109","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ccr.2011.12.017","volume":"21","author":"M Molina-Arcas","year":"2012","unstructured":"Molina-Arcas M, Downward J. How to Fool a Wonder Drug: Truncate and Dimerize. Cancer Cell. 2012;21:7\u20139.","journal-title":"Cancer Cell"},{"key":"3441_CR110","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1038\/emboj.2012.100","volume":"31","author":"M R\u00f6ring","year":"2012","unstructured":"R\u00f6ring M, Herr R, Fiala GJ, Heilmann K, Braun S, Eisenhardt AE, et al. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J. 2012;31:2629\u201347.","journal-title":"EMBO J"},{"key":"3441_CR111","doi-asserted-by":"publisher","first-page":"646","DOI":"10.15252\/embj.201694732","volume":"36","author":"B Diedrich","year":"2017","unstructured":"Diedrich B, Rigbolt KT, R\u00f6ring M, Herr R, Kaeser-Pebernard S, Gretzmeier C, et al. Discrete cytosolic macromolecular <scp>BRAF<\/scp> complexes exhibit distinct activities and composition. The. EMBO J. 2017;36:646\u201363.","journal-title":"EMBO J"},{"key":"3441_CR112","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1002\/cbic.201900266","volume":"20","author":"N Cope","year":"2019","unstructured":"Cope N, Novak B, Candelora C, Wong K, Cavallo M, Gunderwala A, et al. Biochemical Characterization of Full-Length Oncogenic BRAF V600E together with Molecular Dynamics Simulations Provide Insight into the Activation and Inhibition Mechanisms of RAF Kinases. ChemBioChem. 2019;20:2850\u201361.","journal-title":"ChemBioChem"},{"key":"3441_CR113","doi-asserted-by":"publisher","first-page":"5719","DOI":"10.1038\/s41388-018-0365-2","volume":"37","author":"J Yuan","year":"2018","unstructured":"Yuan J, Ng WH, Lam PYP, Wang Y, Xia H, Yap J, et al. The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants. Oncogene. 2018;37:5719\u201334.","journal-title":"Oncogene"},{"key":"3441_CR114","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ccell.2016.06.024","volume":"30","author":"Z Karoulia","year":"2016","unstructured":"Karoulia Z, Wu Y, Tamer, Xin Q, Bollard J, Krepler C, et al. An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. Cancer Cell. 2016;30:485\u201398.","journal-title":"Cancer Cell"},{"key":"3441_CR115","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/neuonc\/nou059","volume":"16","author":"MA Karajannis","year":"2014","unstructured":"Karajannis MA, Legault G, Fisher MJ, Milla SS, Cohen KJ, Wisoff JH, et al. Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro-Oncol. 2014;16:1408\u201316.","journal-title":"Neuro-Oncol"},{"key":"3441_CR116","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.chembiol.2023.07.019","volume":"30","author":"JD Vasta","year":"2023","unstructured":"Vasta JD, Michaud A, Zimprich CA, Beck MT, Swiatnicki MR, Zegzouti H, et al. Protomer selectivity of type II RAF inhibitors within the RAS\/RAF complex. Cell Chem Biol. 2023;30:1354\u201365.e6.","journal-title":"Cell Chem Biol"},{"key":"3441_CR117","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","volume":"30","author":"LB Kilburn","year":"2024","unstructured":"Kilburn LB, Khuong-Quang D-A, Hansford JR, Landi D, Van Der Lugt J, Leary SES, et al. The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med. 2024;30:207\u201317.","journal-title":"Nat Med"},{"key":"3441_CR118","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature10662","volume":"480","author":"PI Poulikakos","year":"2011","unstructured":"Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480:387\u201390.","journal-title":"Nature"},{"key":"3441_CR119","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E\u2013Mutated Colorectal Cancer. N Engl J Med. 2019;381:1632\u201343.","journal-title":"N Engl J Med"},{"key":"3441_CR120","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. N Engl J Med. 2015;372:30\u20139.","journal-title":"N Engl J Med"},{"key":"3441_CR121","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. N Engl J Med. 2010;363:809\u201319.","journal-title":"N Engl J Med"},{"key":"3441_CR122","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358\u201365.","journal-title":"Lancet"},{"key":"3441_CR123","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. N Engl J Med. 2012;367:107\u201314.","journal-title":"N Engl J Med"},{"key":"3441_CR124","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020;383:1207\u201317.","journal-title":"N Engl J Med"},{"key":"3441_CR125","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","volume":"401","author":"AJ De Langen","year":"2023","unstructured":"De Langen AJ, Johnson ML, Mazieres J, Dingemans A-MC, Mountzios G, Pless M, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet. 2023;401:733\u201346.","journal-title":"Lancet"},{"key":"3441_CR126","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","volume":"619","author":"D Kim","year":"2023","unstructured":"Kim D, Herdeis L, Rudolph D, Zhao Y, B\u00f6ttcher J, Vides A, et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature. 2023;619:160\u20136.","journal-title":"Nature"},{"key":"3441_CR127","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","volume":"8","author":"RJ Sullivan","year":"2018","unstructured":"Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, et al. First-in-Class ERK1\/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer Discov. 2018;8:184\u201395.","journal-title":"Cancer Discov"},{"key":"3441_CR128","doi-asserted-by":"publisher","first-page":"e15088","DOI":"10.1200\/JCO.2023.41.16_suppl.e15088","volume":"41","author":"F Taza","year":"2023","unstructured":"Taza F, Durm GA, Opyrchal M, Jalal SI, Radovich M, Schneider BP, et al. A phase 2 basket trial of an ERK1\/2 inhibitor (LY3214996) in combination with abemaciclib for patients whose tumors harbor pathogenic alterations in BRAF, RAF1, MAP2K1\/2, ERK1\/2, and NF1. J Clin Oncol. 2023;41:e15088\u2013e.","journal-title":"J Clin Oncol"},{"key":"3441_CR129","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1093\/oncolo\/oyac237","volume":"28","author":"PM Grierson","year":"2023","unstructured":"Grierson PM, Tan B, Pedersen KS, Park H, Suresh R, Amin MA, et al. Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma. Oncologist. 2023;28:e115\u2013e23.","journal-title":"Oncologist"},{"key":"3441_CR130","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1007\/s12094-022-02916-6","volume":"24","author":"MD Fenor","year":"2022","unstructured":"Fenor MD, Ruiz-Llorente S, Rodr\u00edguez-Moreno JF, Caleiras E, Torrego JC, Sevillano-Fern\u00e1ndez E, et al. MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer. Clin Transl Oncol. 2022;24:2432\u201340.","journal-title":"Clin Transl Oncol"},{"key":"3441_CR131","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1158\/1078-0432.CCR-19-3443","volume":"26","author":"DB Johnson","year":"2020","unstructured":"Johnson DB, Zhao F, Noel M, Riely GJ, Mitchell EP, Wright JJ, et al. Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). Clin Cancer Res. 2020;26:1812\u20139.","journal-title":"Clin Cancer Res"},{"key":"3441_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102137","volume":"92","author":"E Kun","year":"2021","unstructured":"Kun E, Tsang YTM, Ng CW, Gershenson DM, Wong KK. MEK inhibitor resistance mechanisms and recent developments in combination trials. Cancer Treat Rev. 2021;92:102137.","journal-title":"Cancer Treat Rev"},{"key":"3441_CR133","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.1038\/s41388-021-01810-9","volume":"40","author":"R Cronin","year":"2021","unstructured":"Cronin R, Brooke GN, Prischi F. The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistance. Oncogene. 2021;40:3775\u201385.","journal-title":"Oncogene"},{"key":"3441_CR134","doi-asserted-by":"crossref","unstructured":"Irvine M, Stewart A, Pedersen B, Boyd S, Kefford R, Rizos H. Oncogenic PI3K\/AKT promotes the step-wise evolution of combination BRAF\/MEK inhibitor resistance in melanoma. Oncogenesis. 2018;20;7:72.","DOI":"10.1038\/s41389-018-0081-3"},{"key":"3441_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115229","volume":"251","author":"Y Sun","year":"2023","unstructured":"Sun Y, Tang L, Wu C, Wang J, Wang C. RSK inhibitors as potential anticancer agents: Discovery, optimization, and challenges. Eur J Medicinal Chem. 2023;251:115229.","journal-title":"Eur J Medicinal Chem"},{"key":"3441_CR136","doi-asserted-by":"crossref","unstructured":"Beeram M, Wang JS, Chalasani P, Mina L, Patnaik A, Pambid MR, et al. editors. Abstract PS11-33: A first-in-human Phase 1\/1b multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026, a first-in-class oral RSK inhibitor, in metastatic breast cancer patients2021: American Association for Cancer Research.","DOI":"10.1158\/1538-7445.SABCS20-PS11-33"},{"key":"3441_CR137","unstructured":"ClinicalTrials.gov. A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer 2025 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT04586270."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03441-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03441-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03441-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:02:31Z","timestamp":1782705751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03441-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":137,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,7,20]]}},"alternative-id":["3441"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03441-x","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AS is an employee of the Institute of Cancer Research, which has a commercial interest in abiraterone, PARP inhibition in DNA repair\u2013defective cancers, and PI3K\/AKT pathway inhibitors (no personal income). AS has received travel support from Sanofi, Roche\/Genentech, and Nurix, and speaker honoraria from Astellas Pharma and Merck Sharp & Dohme. He has served as an advisor to AbbVie, DE Shaw Research, CHARM Therapeutics, Ellipses Pharma, and Droia Ventures. AS has been the Chief Investigator\/Principal Investigator of industry-sponsored clinical trials. All other authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}